Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors

Breast Cancer Research

Table 2 The concentration of carboplatin in plasma by LC-MS (left) and in xenograft tissues and patient PBMCs by ICP-MS (bottom)

	Tissue	Amount of tissue median (RSE)	Comparison	Method	Subjects (N)	Tissues (N)	Tissues (N) <LOD; <LOQ	Median conc. (RSE %)^a	P
b) Carboplatin	Plasma	50 μL	0.6 h	LC-MS	15	15	0; 0	24 (20)
			5 h	LC-MS	15	15	15; 15	<0.01
Carboplatin adducts	TNBC xenograft tissue	12 μm sections: 1.9 μg DNA (56%)	All	ICP-MS	13	13		0.55 (30%)
			HCC70		5	5		1.85 (42%)	0.091(Cell source)
			MDA-MB-231		3	3		0.55 (23%)
			MDA-MB-436		5	5		0.54 (27%)
			Placebo		5	5		0.476 (57)	0.087 (V yes/no)
			Veliparib 60mg/kg		8	8		0.977 (33)	0.083(Cell source + V)
	PBMCs from patients	Derived from 5–15 mL blood, extracted from a median of 2,160,000 cells			51	51		0.0552 (30%)

MALDI matrix-assisted laser desorption/ionization, TBNC triple negative breast cancer, PBMC peripheral blood mononuclear cells, RSE relative standard errors, ROI region of interest, V veliparib
^aConcentration (Conc.) of veliparib and carboplatin in mg/L, carboplatin adducts in μmol/g DNA
*P value adjusted for dose

ISSN: 1465-542X